Navigation Links
Blue Horizon Stem Cell Treatment Helps Paralyzed Patient Regain Periods of Mobility
Date:7/14/2014

NEW YORK, July 14, 2014 /PRNewswire/ -- Yesenia Torres was an outgoing, popular teenager, with the body of an athlete. the face of a model, and long, beautiful hair. She was turning heads wherever she went.

And then a car accident changed her life forever. Like typical 21 year olds, Yesenia and her two girlfriends were taking a road trip to Florida. An accident caused a suitcase to hit her in the neck, dislocating a vertebrae, and paralyzing her from the chest down.

"It was a total 360 for me, the changes my body experienced really hurt me. I went from living one life to another. It has been a difficult road, but I am a fighter. I am the type of person that won't take no for an answer," said Ms. Torres."Since day one after the accident, I started researching stem cell treatments. I have learned a lot about the benefits of these therapies," she added.

Thanks to stem-cell guru and orthopedic trauma surgeon Dr. Brian Mehling, the Blue Horizon Charitable Foundation, and Yesenia's determination to seek and find innovative stem cell therapies, she has experienced new found energy and mobility she hasn't felt in years.

"It was like a dream come true, I was so happy, I couldn't believe it. Everything went so well.  Just six hours after the treatment, my body was able to do things that were not possible after the accident. Movements started to come back and now I have an increased mobility. I regained sensation in my arms and other parts of my body," Ms. Torres said. "Nothing will hold me back. If I am faced with limitations, I will overcome them."

Today, 18 years after her accident, Yesenia works in the entertainment business, managing music groups and models. She is an avid supporter of stem cell treatments and the Blue Horizon Charitable Foundation.

Uniquely positioned to take advantage of its clinical research, BHSC has safely and efficiently treated more than 600 patients with over 2,600 regenerative procedures documenting each procedure while tracking the progress of patients through their treatment cycle. Blue Horizon International Stem Cell Therapy Program is associated with The Stem Cell Centre, Hongqiao Brain Hospital and Wuhan University School of Basic Medical Science, Wuhan, China. A new lab and treatment center for orthopedic therapies is scheduled to open at Medissimo Hospital and Clinic in May 2014. For more information, please visit www.bluehorizonstemcells.com.

Blue Horizon International is a healthcare consulting company with a unique concept that combines treatment, research, and philanthropic efforts. BHI provides the highest quality care and services available in surgical and medical treatments globally, the most advanced technologies currently available in stem cell therapies, and also provides resources needed to assist children and adults who are medically underserved. For more information, please visit www.bluehorizoninternational.com.

PRLog ID: www.prlog.org/12311049


'/>"/>
SOURCE Blue Horizon Charitable Foundation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Blood Test on the Horizon to Detect Aortic Aneurysm and Aortic Dissection
2. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
3. Bacteria supplemented their diet to clean up after Deep Water Horizon oil spill
4. SPIE Leaders Urge Photonics Community to Assert Need for Full Horizon 2020 Funding
5. Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon
6. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
7. Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion
8. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
9. Gordon Hunter Prescribes Treatment for an Ailing Environment in New Book
10. Accumed Research Associates Featured On Katz's Corner 77 WABC Radio Show To Discuss Enlarged Prostate Treatment and Clinical Trials In Urology
11. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... formation of its Medical/Clinical Advisory Board.  This new ... who enhance the range and depth of expertise ... its novel prenatal diagnostic tests.  These experts are ... guidance for the company,s product development and commercialization ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... , ... January 19, 2017 , ... FireflySci Inc. is ... rate. The tremendous growth is accounted to two main factors. The first ... the expanding network of vendors supplying FireflySci products all around the world. , 2016 ...
Breaking Biology Technology:
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):